Hyperphosphatemia

Patients on hemodialysis who received dietary counseling on the phone during the COVID-19 pandemic experienced improvements in a variety of parameters associated with nutritional status, according to study findings.

Patients with chronic kidney disease on maintenance dialysis experienced improved control of hyperphosphatemia with a dual treatment of tenapanor and phosphate binders compared with the latter alone, according to a study.

Compared with standard targets, lower serum phosphate levels led to smaller changes in coronary artery calcification scores, suggesting stricter phosphate control may delay calcification progression for patients on hemodialysis.

Adding to data from clinical trials demonstrating the efficacy of sucroferric oxyhydroxide in phosphate management for patients on hemodialysis, researchers from Spain have identified several benefits of the drug in “real-world” settings.

Phosphate binder lanthanum carbonate increased systolic blood pressure in patients with chronic kidney disease, leading researchers to suggest the drug “may reduce gastrointestinal absorption of antihypertensive medications.”

A meta-analysis of clinical trials suggested that diet therapy focused on lowering serum phosphate levels may be safe and effective for patients on hemodialysis, but researchers emphasized that further investigation is required.

A study of patients who received dialysis at centers across the United States revealed no link between neighborhood food environment – including access to “healthy foods” and socioeconomic status – and hyperphosphatemia.

Ardelyx Inc. recently announced the FDA has accepted its new drug application of tenapanor for the control of serum phosphorus in adult patients with chronic kidney disease on dialysis.

Study results showed patients on hemodialysis who received a modified low-phosphorous diet had similar phosphate levels as those receiving the standard diet, with the modified diet widening patients’ food choice and increasing fiber intake.

An association was found between uremic pruritis and adverse long-term outcomes for patients on dialysis, according to a study published in the Journal of the American Academy of Dermatology.